Cognitive Impairment Disorders Treatment Market

Market Overview:

Cognitive disorder implies to any type of disease, disorder or condition that harms the cognitive functioning of the person which results in improper functioning of the brain. Cognitive disorders involve memory problems and causes impairment in the functioning of brain. The major cognitive impairment disorders are delirium, dementia and amnestic disorder.

Cognitive impairment varies from mild to severe. With mild cognitive impairment, patients experience mild symptoms but as the cognitive impairment becomes severe, patients started losing its thinking ability and as a result leads to complete memory loss. Alzheimer’s disease and other dementias with respect to conditions such as stroke, developmental disabilities and traumatic brain injury can lead to cognitive impairment.

According to Center for Disease Control and Prevention report statistics, more than 16 million people in the United States are living with cognitive impairment. Cognitive impairment mostly affects people of age 65 years or older.

The global cognitive impairment disorders treatment market will contribute substantial revenue generation in the market owing to rising burden of cognitive impairment, growing number of aging population and increasing economic burden is likely to stimulate the growth of cognitive impairment disorders treatment market.

Moreover, increase in brain injuries, chronic diseases such as Parkinson’s disease, diabetes and stroke may drive the cognitive impairment disorders treatment market. Currently, no cure has been developed to treat cognitive impairment caused by Alzheimer disease since date. Drugs that are approved for the treatment of Alzheimer’s disease has not shown benefit in treating cognitive impairment and thus it may hinder the growth of cognitive impairment disorders treatment market.

Market Segmentation:

Drug Class	Antiepileptic Drugs Cognitive Impairment Disorders Treatment Antipsychotics Drugs Cognitive Impairment Disorders Treatment
Therapies Type	Symptomatic therapies Cognitive Impairment Disorders Treatment Cholinesterase inhibitors Cognitive Impairment Disorders Treatment Nootropic medications Cognitive Impairment Disorders Treatment Ginkgo biloba Cognitive Impairment Disorders Treatment Memory stimulants Cognitive Impairment Disorders Treatment Preventive therapies Cognitive Impairment Disorders Treatment Anti-oxidants Omega fatty acids Homocysteine Cholinesterase inhibitors Estrogen Anti-inflammatory agents Anti-amyloid therapies Statins Therapy for vascular risk factors
End User	Hospital Pharmacies Specialty Clinics Retail Pharmacies Drug Stores Mail Order Pharmacies Ambulatory Surgical Centers

Regional Outlook:

Geographically, cognitive impairment disorders treatment market is categorized into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to contribute substantial revenue in cognitive impairment disorders treatment market due to rising burden of cognitive impairment, high healthcare expenditure and availability of drugs which as a result increases the growth of cognitive impairment disorders treatment market.

Similarly Europe intend to have increasing growth in cognitive impairment disorders treatment market owing to advancement in technology and also growing incidences of cognitive impairment that leads to growth of cognitive impairment disorders treatment market.

Asia Pacific seems to have potential growth in cognitive impairment disorders treatment market due to high demand of treatment medication and rising economy which as a result leads to the growth of cognitive impairment disorders treatment market.

Japan also contribute significant growth in cognitive impairment disorders treatment market due to growing aging population, increasing government initiatives in the region propel the growth of cognitive impairment disorders treatment market.

Middle East and Africa have less contribution towards the growth of cognitive impairment disorders treatment market due to poor healthcare facilities, low economy and less availability of treatment options that may impact the growth of cognitive impairment disorders treatment market.

Key Players:

Some of the key players leading in cognitive impairment disorders treatment market are: Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Minerva Neurosciences, Intra-Cellular Therapies, Avineuro Pharmaceuticals, SyneuRx, Lundbeck, AB Science SA, AbbVie Inc, CHA Bio & Diostech Co Ltd, Echo Pharmaceuticals BV, Eisai Co Ltd, GlaxoSmithKline Plc, Grifols SA, Immungenetics AG, Otsuka Holdings Co Ltd, Merck & Co Inc, Kyowa Hakko Kirin Co Ltd and others.

The report covers exhaustive analysis on:

• Cognitive Impairment Disorders Treatment Market Segments
• Cognitive Impairment Disorders Treatment Market Dynamics
• Historical Actual Market Size, 2013 - 2017
• Cognitive Impairment Disorders Treatment Market Size & Forecast 2018 to 2028
• Cognitive Impairment Disorders Treatment Current Trends/Issues/Challenges
• Competition & Companies involved
• Cognitive Impairment Disorders Treatment Market Drivers and Restraints

Regional analysis includes:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

To know more about delivery timeline for this report Contact Sales